PO.MCB08.02 · 分子与细胞生物学

Systematic discovery and classification of structural variant drivers across >8,000 TCGA whole genomes

海报缩略图:Systematic discovery and classification of structural variant drivers across >8,000 TCGA whole genomes
编号 1989 展板 15 时间 4/20 09:00–12:00 区域 Section 23 主讲 Antonia Kowalewski, BS
分会场 Genomic Drivers of Cancer Pathogenesis
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Antonia Kowalewski1, Xavi Loinaz1, Hansol Park2, Vasuki Narasimha Swamy1, David Heiman1, Samantha Van Seters1, Saveliy Belkin1, Sam Wiseman1, Chunyang Bao2, Andrew D. Cherniack1, Luis A. Corchete Sanchez1, Brian P. Danysh1, Zachary Everton1, Ryul Kim2, Gang-Hee Lee2, Won-Chul Lee2, David Lehotzky1, Ron Solan1, Chip Stewart1, Haruna Tomono1, Gengchao Wang1, Rameen Beroukhim1, Young Seok Ju2, Esther Rheinbay1, Gad Getz1

1Broad Institute, Cambridge, MA,2Inocras Inc., San Diego, CA

摘要 Abstract

Structural variants (SVs)-large-scale genomic deletions, duplications, inversions, and translocations-can promote tumorigenesis by activating proto-oncogenes, disrupting tumor suppressors, generating oncogenic fusions, rewiring gene regulation, and mediating catastrophic events such as chromoplexy and chromothripsis. Yet, the role of SVs as cancer-driving mutations remains less comprehensively characterized than that of single-nucleotide variants or indels, largely due to the historic scarcity of tumor whole-genome sequencing data required for accurate SV detection. In this study, we analyzed whole-genome sequencing data from >8,000 tumor-normal pairs spanning 31 cancer types from The Cancer Genome Atlas (TCGA) to systematically characterize SVs at unprecedented scale. Compared with the flagship Pan-Cancer Analysis of Whole Genomes (PCAWG) project, our analysis includes roughly four times as many samples and six additional cancer types. Somatic SVs were identified using a custom pipeline combining Manta and dRanger with optimized downstream filters. Across all tumors, we detected >1 million somatic SVs. We developed two complementary frameworks to interpret these variants. First, to classify SVs by their genomic architecture, we inferred genomic segments and their associated copy number alterations driven by SVs ranging from a single to hundreds of breakpoints, enabling the generalization of distinct patterns through unsupervised clustering. Second, to identify candidate driver genes, we developed SVelfie, a statistical framework that detects genes significantly enriched in functional SVs predicted to confer gain- or loss-of-function effects. Applying SVelfie to 385 prostate and 333 ovarian cancer genomes revealed multiple novel candidate driver genes, with additional discoveries expected as analysis extends to the full >8,000-sample dataset. This work represents the most comprehensive analysis to date of SV drivers in cancer. By uniting large-scale WGS data with new computational frameworks for SV classification and driver detection, we expand the catalog of SV-driven cancer genes, illuminate mechanisms of SV-mediated oncogenesis, and advance the clinical utility of whole-genome sequencing in precision oncology.
利益披露 Disclosure
A. Kowalewski, None.. X. Loinaz, None.. H. Park, None.. V. Narasimha Swamy, None.. D. Heiman, None.. S. Van Seters, None.. S. Belkin, None.. C. Bao, None. A. D. Cherniack, Bayer ). L. A. Corchete Sanchez, None.. B. P. Danysh, None.. Z. Everton, None.. R. Kim, None.. G. Lee, None.. W. Lee, None.. D. Lehotzky, None.. H. Tomono, None.. G. Wang, None. R. Beroukhim, Karyoverse Stock. LOH Therapeutics Stock. Y. Ju, None. E. Rheinbay, Inocras Inc. ). G. Getz, IBM ). Pharmacyclics/Abbvie ). Bayer ). Genentech ). Calico ). Ultima Genomics ). Inocras Inc. ). Google ). Kite ). Novartis ). Broad Institute Patent. Scorpion Therapeutics Other Securities. Predicta Biosciences Other Securities. Antares Therapeutics Other Securities.

在会议检索中打开